Free Trial

29,694 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Acquired by Y Intercept Hong Kong Ltd

Dyne Therapeutics logo with Medical background

Y Intercept Hong Kong Ltd purchased a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 29,694 shares of the company's stock, valued at approximately $1,067,000.

Several other large investors also recently modified their holdings of DYN. State of New Jersey Common Pension Fund D purchased a new stake in Dyne Therapeutics in the 3rd quarter valued at $1,588,000. Seven Eight Capital LP increased its holdings in Dyne Therapeutics by 195.7% during the second quarter. Seven Eight Capital LP now owns 53,739 shares of the company's stock worth $1,896,000 after buying an additional 35,568 shares during the last quarter. Jennison Associates LLC raised its position in Dyne Therapeutics by 1.5% in the third quarter. Jennison Associates LLC now owns 1,346,952 shares of the company's stock worth $48,383,000 after acquiring an additional 19,730 shares during the period. Mutual of America Capital Management LLC purchased a new position in Dyne Therapeutics in the second quarter valued at about $1,724,000. Finally, Victory Capital Management Inc. bought a new position in shares of Dyne Therapeutics during the 2nd quarter valued at approximately $676,000. Institutional investors and hedge funds own 96.68% of the company's stock.

Insider Transactions at Dyne Therapeutics

In related news, SVP Richard William Scalzo sold 1,390 shares of the business's stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $48,024.50. Following the transaction, the senior vice president now owns 98,568 shares in the company, valued at $3,405,524.40. The trade was a 1.39 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Susanna Gatti High sold 8,976 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total value of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares in the company, valued at approximately $4,529,594.76. This represents a 6.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 180,046 shares of company stock worth $6,300,265. Company insiders own 20.77% of the company's stock.

Dyne Therapeutics Stock Performance

DYN traded up $0.12 on Friday, reaching $25.73. The company had a trading volume of 840,351 shares, compared to its average volume of 1,445,920. Dyne Therapeutics, Inc. has a 52-week low of $11.51 and a 52-week high of $47.45. The company has a market cap of $2.62 billion, a price-to-earnings ratio of -7.11 and a beta of 1.09. The business has a 50 day simple moving average of $30.53 and a 200 day simple moving average of $35.24.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). As a group, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. StockNews.com downgraded Dyne Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, September 16th. Piper Sandler reiterated an "overweight" rating and set a $53.00 price target on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Guggenheim lifted their price objective on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday, August 15th. Robert W. Baird initiated coverage on shares of Dyne Therapeutics in a report on Friday. They set an "outperform" rating and a $46.00 price objective on the stock. Finally, Oppenheimer reiterated an "outperform" rating and issued a $55.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $50.42.

View Our Latest Report on Dyne Therapeutics

Dyne Therapeutics Profile

(Free Report)

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Read More

Institutional Ownership by Quarter for Dyne Therapeutics (NASDAQ:DYN)

→ Has Trump Finally Gone Too Far? (From Insiders Exposed) (Ad)

Should you invest $1,000 in Dyne Therapeutics right now?

Before you consider Dyne Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.

While Dyne Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?
SoundHound Stock Explodes Again – Is a Major Breakout Coming?
How Fintech Strategy at FinWise Bancorp and CEO Vision Are Driving 78% Gains

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines